Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...($333404 $320558 4% ...),Health

Date:8/18/2009

$333,404 $320,558 4% ======== ======== Adjusted operating expenses % 16.6% 18.5% Reported operating income $247,307 $194,858 27% Inventory step-up - Unico 1,062 - Inventory step-up - Diba 1,503 - Inventory step-up - JB Labs 358 - Inventory step-up - Galpharm - 5,756 Impairment of fixed assets 1,600 - Impairment of intangible asset - 10,346 Loss on asset exchange 639 - Restructuring costs - Germany 14,647 - Restructuring costs - West Coast - 491 Restructuring costs - United Kingdom - 1,821 Write-off of in-process R&D - Diba acquisition 279 - Write-off of in-process R&D - Galpharm acquisition - 2,786 ----- ----- Adjusted operating income $267,395 $216,058 24% ======== ======== Adjusted operating income % 13.3% 12.5% Reported income from continuing operations $141,098 $140,197 1% Inventory step-up - Unico (5) 645 - Inventory step-up - Diba (1) 1,082 - Inventory step-up - JB Labs (2) 229 - Inventory step-up - Galpharm (1) - 4,144 Impairment of fixed asset
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend